ANAB · sample dossier
AnaptysBio, Inc. Common Stock
37/100
OutdatedGenerated Sep 5, 2026 · 10:00 AM UTC · 62 days ago
This copy is frozen (Sep 5). Sign in to run the same work — filings, valuation, bull and bear, sources — on any US stock or ETF, in about 90 seconds.
Run a fresh dossierANAB
EquityAnaptysBio, Inc. Common Stock · XNAS
Decision context
Recommendation
Weighed down by weak Value (3/100) and Growth (4/100) scores.
A cautious picture — if you own it, consider taking some off.
AlphaDog Fair Value
Executive thesis & key metrics
Executive Investment Thesis
AnaptysBio, Inc. is a biotechnology company with a market capitalization of $1.68B, trading at an EV/EBITDA multiple of 39.76 and a Price/Book ratio of 129.38. The company faces operational contraction marked by an annual revenue decline of -8.0%, a negative net margin of -11.5%, and an elevated Debt/Equity ratio of 21.76. The single biggest risk to the firm is unprofitability reflected in a P/E ratio of -55.69 combined with high financial leverage of 21.76 Debt/Equity.
Key Metrics to Watch
What changed recently
No material changes found in the last 30 days.
Why this rating
Score 37 · Sell
Data through
OutdatedMar 31, 2026
Momentum 83/100 — 1Y return 304%.
Levels unavailable — AlphaDog quantitative valuation model did not produce an estimate from comps or DCF
Re-evaluate if
- Net margin falls below -9.2% (was -11.5%)
- Price moves back above the 50-day moving average.
Trim / reconsider if
- ROA falls below 4.4% (was 6.8%)
- Net margin drops below -11.5%
- Debt/Equity increases beyond 21.76.
Think of these dollars as a map of our value estimate for Sell — helpful context, not a reason to override the view.
A Calmer Look · Devil's Advocate
The prevailing consensus and debate ruling anchor on a 'Reduce' verdict by fixating on an extreme Debt/Equity ratio of 21.76 and a negative net margin of -11.5%.
May be overlooked
The consensus treats Debt/Equity of 21.76 as acute credit risk, ignoring that depleted book equity distorts the ratio while the Altman Z-score of 5.33 indicates balance sheet stability.
Bears dismiss the company as an unprofitable cash burner, completely overlooking the positive ROA of 6.8% and positive trailing free cash flow per share of $0.28.
The synthesis report relies on stale 10-K filings from 2025-02-27 (over 550 days old, violating the 90-day currency standard) to evaluate ongoing ASC 606 collaboration terms.
Expectations look stretched
Bull claims celebrate cluster insider purchases of 18,090 shares on 2026-06-15 as high-conviction buying, ignoring that the shares were acquired at $0 as equity compensation.
Relying on the 304.0% 1-year return ignores immediate technical breakdown, with the stock falling below its 50-day moving average alongside a mediocre Piotroski F-score of 4/9.
Assuming ASC 606 milestone payments will promptly reverse the -8.0% top-line contraction relies on unhedged clinical trial assumptions rather than guaranteed contractual cash flow.
Revenue growth YoY improves above -8.0%.
Revenue growth YoY improves above -8.0%.
Monitor These Triggers
3 Checkpoints · Next PrintRevenue Growth YoY (baseline: -8.0%)
Market context
Snapshot returns at report publication
1 month
+3.7%
3 months
+12.8%
6 months
+53.8%
1 year
+304.0%
At a Glance
A smaller company has mixed momentum at unprofitable earnings.
Top Holders
Financial trajectory
Financial Performance
Go deeper
For learning and research only — not investment advice. AlphaDog doesn’t hold stocks and isn’t your financial advisor.
Run the next one yourself.
You just read a full ANAB dossier — scored verdict, valuation, and both sides, with sources. Sign in to run that on a name you hold, on current filings. A free account includes 10 credits a week, 1 per fresh run.